Below are the most recent publications written about "Multiple Sclerosis" by people in Profiles.
-
Gusovsky AV, Lin CC, Kerber K, Reynolds EL, Callaghan BC, Burke JF. Costs Are Still on the Rise for Commonly Prescribed Branded Neurologic Medications. Neurology. 2024 Nov 26; 103(10):e210029.
-
Kalatskaya I, Giovannoni G, Leist T, Cerra J, Boschert U, Rolfe PA. Revealing the immune cell subtype reconstitution profile in patients from the CLARITY study using deconvolution algorithms after cladribine tablets treatment. Sci Rep. 2023 May 18; 13(1):8067.
-
Kenney R, Liu M, Hasanaj L, Joseph B, Al-Hassan AA, Balk L, Behbehani R, Brandt AU, Calabresi PA, Frohman EM, Frohman T, Havla J, Hemmer B, Jiang H, Knier B, Korn T, Leocani L, Mart?nez-Lapiscina EH, Papadopoulou A, Paul F, Petzold A, Pisa M, Villoslada P, Zimmermann H, Ishikawa H, Schuman JS, Wollstein G, Chen Y, Saidha S, Thorpe LE, Galetta SL, Balcer LJ. Normative Data and Conversion Equation for Spectral-Domain Optical Coherence Tomography in an International Healthy Control Cohort. J Neuroophthalmol. 2022 12 01; 42(4):442-453.
-
Skarlis C, Markoglou N, Gontika M, Bougea A, Katsavos S, Artemiadis A, Chrousos G, Dalakas M, Stefanis L, Anagnostouli M. First-line disease modifying treatments in pediatric-onset multiple sclerosis in Greece: therapy initiation at more advanced age is the main cause of treatment failure, in a retrospective observational study, with a cohort from a single Multiple Sclerosis Center. Neurol Sci. 2023 Feb; 44(2):693-701.
-
Stefano N, Sormani MP, Giovannoni G, Rammohan K, Leist TP, Coyle PK, Dangond F, Alexandri N, Galazka A. Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5?years: a plain language summary. Neurodegener Dis Manag. 2022 12; 12(6):303-310.
-
Covey TJ, Golan D, Zarif M, Bumstead B, Buhse M, Kaczmarek O, Sergott R, Wilken J, Sima DM, Van Hecke W, Gudesblatt M. Individual differences in visual evoked potential latency are associated with variance in brain tissue volume in people with multiple sclerosis: An analysis of brain function-structure correlates. Mult Scler Relat Disord. 2022 Dec; 68:104116.
-
Covey TJ, Golan D, Doniger GM, Sergott R, Zarif M, Bumstead B, Buhse M, Kaczmarek O, Mebrahtu S, Bergmann C, Wilken J, Gudesblatt M. Prolonged visual evoked potential latency predicts longitudinal worsening of fatigue in people with multiple sclerosis. Mult Scler Relat Disord. 2022 Nov; 67:104073.
-
Rasouli J, Casella G, Zhang W, Xiao D, Kumar G, Fortina P, Zhang GX, Ciric B, Rostami A. Transcription Factor RUNX3 Mediates Plasticity of ThGM Cells Toward Th1 Phenotype. Front Immunol. 2022; 13:912583.
-
Kenney RC, Liu M, Hasanaj L, Joseph B, Abu Al-Hassan A, Balk LJ, Behbehani R, Brandt A, Calabresi PA, Frohman E, Frohman TC, Havla J, Hemmer B, Jiang H, Knier B, Korn T, Leocani L, Martinez-Lapiscina EH, Papadopoulou A, Paul F, Petzold A, Pisa M, Villoslada P, Zimmermann H, Thorpe LE, Ishikawa H, Schuman JS, Wollstein G, Chen Y, Saidha S, Galetta S, Balcer LJ. The Role of Optical Coherence Tomography Criteria and Machine Learning in Multiple Sclerosis and Optic Neuritis Diagnosis. Neurology. 2022 Sep 13; 99(11):e1100-e1112.
-
Lind J, Persson S, Vincent J, Lindenfalk B, Oliver BJ, Smith AD, Andersson G?re B. Contact patterns and costs of multiple sclerosis in the Swedish healthcare system-A population-based quantitative study. Brain Behav. 2022 06; 12(6):e2582.